VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
DVAXDynavax Technologies Corporation
$15.50$1.8B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksDVAXPrice Target
DVAX logo

Dynavax Technologies Corporation (DVAX) Price Target Analysis

Updated Jun 18, 2026
Analyst Rating: Buy
Based on 11 analysts

74.2% Below Target

DVAX trades 74.2% below Wall Street's consensus target of $27.00.

Current Price$15.50
Average Target$27.00
Target
Current
Low$20.00
Median$29.00
High$32.00

Analyst Target Range

Forward P/E31.6x
(Growth Premium)
PEG Ratio—
Implied Growth+254.3%
(High Growth)
Analyst Spread44.4%
(Moderate)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$15.50
Consensus$27.00
High$32.00
Low$20.00

Consensus Scenario Assumptions

The base valuation assumes DVAX achieves its forward estimates and maintains a stable P/E multiple of 31.6x. This scenario reflects the blended consensus of 11 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 11 published analyst recommendations for DVAX

9/11 analysts are bullish
+36
BearishBullish
Weighted analyst sentiment score based on 11 ratings
ConsensusBuy
Coverage11 Analysts
Net Score+36
Bull / Bear82% / 9%
Strong Buy00%
Buy982%
Hold19%
Sell19%
Strong Sell00%
Strong Buy
00%
Buy
982%
Hold
19%
Sell
19%
Strong Sell
00%
Recommendation Mix82% Buy · 9% Hold · 9% Sell
Buy (9)Hold (1)Sell (1)

DVAX Price Target Analysis

Updated June 22, 2026

As of June 22, 2026, Dynavax Technologies Corporation (DVAX) has a Wall Street consensus price target of $27.00, based on estimates from 11 covering analysts. With the stock currently trading at $15.50, this represents a potential upside of +74.2%. The company has a market capitalization of $1.82B.

Analyst price targets range from a low of $20.00 to a high of $32.00, representing a 44% spread in expectations. The median target of $29.00 differs from the mean, suggesting potential outlier estimates.

The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.

From a valuation perspective, DVAX trades at a trailing P/E of 77.5x and forward P/E of 31.6x. Analysts expect EPS to grow +254.3% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.96, with bear and bull scenarios of $0.60 and $1.26 respectively. Model confidence stands at 48/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+52.5%
Industry Consensus
Avg Forward P/E
11.5x
(Value)
Peers with Coverage
9 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
NVAX logo
NVAXNovavax, Inc.
$1.5B$9.13$18.00
+97.2%
Buy—23
SIGA logo
SIGASIGA Technologies, Inc.
$310M$4.32——Buy2.5x1
IMVT logo
IMVTImmunovant, Inc.
$7.3B$35.34$45.00
+27.3%
Buy—23
VXRT logo
VXRTVaxart, Inc.
$133M$0.55$2.00
+263.0%
Buy—3
IBRX logo
IBRXImmunityBio, Inc.
$7.7B$7.36$13.00
+76.6%
Buy—5
PFE logo
PFEPfizer Inc.
$143.5B$25.22$26.75
+6.1%
Hold8.5x39
MRK logo
MRKMerck & Co., Inc.
$281.2B$113.87$131.58
+15.6%
Buy22.2x37
GSK logo
GSKGSK plc
$101.9B$50.67$52.45
+3.5%
Hold14.0x29
SNY logo
SNYSanofi
$102.4B$42.38$51.00
+20.3%
Buy10.1x27
MRNA logo
MRNAModerna, Inc.
$25.4B$63.96$40.29
-37.0%
Hold—27

DVAX — Frequently Asked Questions

Quick answers to the most common questions about buying DVAX stock.

What is the DVAX stock price target for 2026?

The consensus Wall Street price target for DVAX is $27, representing 74.2% upside from the current price of $15.5. With 11 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is DVAX a buy, sell, or hold?

DVAX has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $27 implies 74.2% upside from current levels.

Is DVAX stock overvalued or undervalued?

DVAX trades at a forward P/E of 31.594x, representing a moderate valuation. With analysts targeting $27 (74.2% implied move), the stock appears reasonably valued with upside.

How high can DVAX stock go?

The most bullish Wall Street analyst has a price target of $32 for DVAX, while the most conservative target is $20. The consensus of $27 represents the median expectation. Our quantitative valuation model projects a bull case target of $1 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover DVAX stock?

DVAX is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 1 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the DVAX stock forecast?

The 12-month DVAX stock forecast based on 11 Wall Street analysts shows a consensus price target of $27, with estimates ranging from $20 (bear case) to $32 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $1, with bear/bull scenarios of $1/$1.

What is DVAX's fair value based on fundamentals?

Our quantitative valuation model calculates DVAX's fair value at $1 (base case), with a bear case of $1 and bull case of $1. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 48/100.

What is DVAX's forward P/E ratio?

DVAX trades at a forward P/E ratio of 31.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 77.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy DVAX stock?

Wall Street analysts are very optimistic on DVAX, with a "Buy" consensus rating and $27 price target (74.2% upside). 9 of 11 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do DVAX price targets vary so much?

DVAX analyst price targets range from $20 to $32, a 44% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $27 consensus represents the middle ground. Our model's $1-$1 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare